Description CAPITALAND MALAYSIA TRUST ("CLMT") - Revision of Trustee Fee The Board of Directors (the “Board”) of CapitaLand Malaysia REIT Management Sdn. Bhd. (“CMRM”), the manager of CLMT, wishes to announce that the Trustee Fee of CLMT has been revised from the existing fee of RM400,000 per annum to RM440,000 per annum, with effect retrospectively from 1 July 2023 (the “Revision”). ~~~~~~~~~~~~~~~~~~~~~~~~~~
@BursaVulture If this is the case, I think karma hit him hard. I know he was promoting SD very hard and has been written many articles when SD dropped, even later SD was suspended he kept on writing hysterically but I do not know in the earlier stage, he tried to push down the price for collection. He also keen to argue with others with different opinions aggressively. He probably bets on SD heavily and badly hurt.
There is nothing new about part of the payment was received from the gov. and remain balance to be paid, ICPT is an ongoing process ...... the only thing is, it can only be registered to the account when the amount was received but the date and amount of the payment is depend on gov. .....
As at to date, TNB has already received full payment of the surcharge amounting to RM10.4 billion from the Government for the ICPT period from 1 January 2023 to 30 June 2023.
The Government has decided a total subsidy allocation of RM5.2 billion and introduced targeted subsidy scheme (‘Scheme’) for ICPT implementation period from 1 July 2023 until 31 December 2023.
Performance of the current second quarter (three months) FY2023 against the corresponding second quarter (three months) FY2022:
Revenue for the quarter under review increased from RM12,837.7 million to RM13,323.2 million, resulted from higher sales of electricity by 3.5% or RM434.2 million.
Operating profit for the current quarter decreased by 28.9% or RM759.6 million due to the lower ICPT under recovery recognised in the current quarter of RM2,860.2 million as compared to RM6,302.6 million in the last corresponding quarter, offset by lower operating expenses of RM2,328.1 million.
Profit after taxation decreased by RM634.7 million, from RM905.6 million in the last corresponding period to RM270.9 million in the quarter under review. This was due to negative fuel margins and foreign exchange translation losses in the current quarter.
~~~~~~~~~~~~~ Imbalance Cost Past-Through (ICPT) often creates unpredictable outcome 😐
Revenue for the quarter improved by 4.2% compared to the corresponding second quarter of 2022, increased from RM 1.75 billion to RM 1.82 billion, while decreased by 7.2% against those of the preceding first quarter of 2023 which were RM 1.96 billion. The improved revenue in comparison to the corresponding second quarter of 2022 was due to higher sales recorded in Healthcare and Others segments coming from new clients and ongoing growth of existing clients in Healthcare segment and higher outlet sales for Others segment with resumption of batter supply. Revenue declined compared to the preceding first quarter of 2023, largely due to Ramadan being in early Q2 in Consumer Goods segment which created higher festive sales in preceding first quarter coupled with change in sales mix in Healthcare segment.
Operating expense for the quarter increased 4.8% from RM 1.70 billion to RM 1.79 billion compared to the corresponding second quarter of 2022, while decreased by 6.6% against those of the preceding first quarter of 2023 which were at RM 1.91 billion. The changes in operating expenses were largely in line with the movement in revenue. The operating expense increased more than the revenue growth as compared to the corresponding second quarter of 2022 were largely due to higher cost base to support future growth.
Profit before tax for the quarter decreased by 23.9% compared to the same quarter of 2022 and decreased by 34.6% as compared to the preceding first quarter of 2023. The decline as compared to the corresponding second quarter of 2022 was the outcome of higher operating expense as above-mentioned and higher foreign exchange loss. The decrease in profit before tax against preceding first quarter of 2023 was due to lower sales.
Is not fine tuned in many ways, 1. when reading the threads in forum mode, can't tab to access to the related counter info. The old App has this function at the top title bar. 2. while there are improvements in stock info page, only daily movement graph is shown. The old App has the options up to yearly graph. 3. always jam while typing longer ( I use desktop to type after failed twice) 4. until now, i can't find a way to organize counters in the portfolio in alphabetical order
The "private value" of USD200-300 has been mentioned for many years. TauRx is a 30 year old "company". . . . The payoff might not be there. Don't buy GENTING just because it owned 20% of TauRx ... Buy GENTING for other reasons. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I don't know how many get the meaning wrong about this reporting.
Basically, the trio from east Malaysia were responded to a group of Muslim’s NGOs from peninsular, mainly from KL and Selangor, urged to establish a Malay-Muslim government without DAP ..... the east Malaysia organisations voiced their strong disagreement by saying that let the east Malaysia leaves Malaysia before that happens.
savemalaysia is not the author of this article, he merely serves i3 forum by pasted this article from focusmalaysia, a online portal. The original location of the article can be accessed through the link provided at the bottom of the article.
Reminder, On behalf of the Board of the Manager, CIMB wishes to announce that the Proposed Placement has been completed following the listing and quotation of 464,997,500 Placement Units on the Main Market of Bursa Securities today. The issuance of the Placement Units raised gross proceeds of approximately RM227.85 million based on the issue price of RM0.49 each.
With the listing of the Placement Units, the total enlarged number of issued CLMT units is 2,671,932,995.
TauRx’s deliver Alzheimer’s disease therapy results 17th July 2023 Company’s hydromethylthionine mesylate therapy reduced neurodegeneration during pivotal trial
TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial. . . Henrik Zetterberg, professor of neurochemistry at UCL Queen Square Institute of Neurology, concluded: “NfL is a well studied biomarker with wide applicability to different neurological disorders, including AD.
“Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”
TauRx now intends to submit the HMTM results from LUCIDITY and previous trials for regulatory approval in the US, UK and several other territories.
Some info. about Taurx from google: Where is TauRx located? Singapore, TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
Who is the CEO of TauRx? Professor Claude Wischik For three decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to find an effective treatment for neurodegenerative disease. Professor Wischik is a board-certified psychiatrist and holder of a Chair in Mental Health at the University of Aberdeen.
Proposed Special Dividend = 0.10 Proposed Capital Repayment = 0.75 Total = 0.85
Upon completion of the Proposed Disposal, PICB may be classified as a “Cash Company” and/or an “Affected Listed Issuer”. If so, the continuous listing of PICB on the Main Market of Bursa Securities is dependent on the ability of the Board and management to formulate a regularisation plan within the stipulated period.
On behalf of AEON Credit, AmInvestment Bank is pleased to announce that Bursa Securities had, vide its letter dated 31 July 2023, approved the listing of and quotation for 255,307,690 new ordinary shares to be issued pursuant to the Proposed Bonus Issue
Not sure how they are going to fulfill the 12. 50 % Bumis equity participation ..... if through new shares issuance, there would be another block of shares issued in low price, that poised for disposing ....
Don't intend to post here, just because coincidentally I did a little search on this counter, just drop a few lines, for those interested.
I would delay to go in, until a fair price. The RI with issued price @23.5 sen, was under subscribed by 27% (this probably taken up by under writer), the new shares still not listed. I suspect the price has been pushed up recently is for distribution preparation ;-)